New nurse-led protocols for stroke patients, based on ACU research, led by the Nursing Research Institute, have resulted in changes to policy, guidelines and clinical practice in Europe and Australia. The protocols were developed through the Quality in Acute Stroke Care (QASC) Trial (published in the Lancet, 2011) to manage fever, hyperglycaemia and swallowing (FeSS) post-stroke.
Professor Sandy Middleton FACN, FAAN is a Professor of Nursing and Director of the Nursing Research Institute at St Vincent’s Health Network Sydney, St Vincent’s Hospital Melbourne and Australian Catholic University. She focusses on stroke and the way research can improve care, particularly analysing the way nurses can initiate care to improve patient recovery.
Professor Middleton was the lead investigator on the landmark NHMRC-funded QASC cluster trial that demonstrated decreased death and dependency following implementation of nurse-initiated protocols to manage fever, hyperglycaemia and swallowing post-stroke, winning multiple national and international awards including ACU’s Vice-Chancellor’s Staff Excellence Award, Excellence in Research and Research Partnerships in 2019. These protocols have been translated into 64 hospitals in 17 European countries and in adopted in 36 NSW hospitals. She has published in high impact journals including The Lancet and The New England Journal of Medicine.
Australian Health Journal spoke with Professor Sandy Middleton on these significant achievements in nurse-led acute stroke care.
You Might also like
-
The Case for Embedded Pharmacy in Residential Aged Care
Embedded pharmacy in residential aged care has been successful in South Australia at the Tanunda Lutheran Home in the Barossa Valley. Julian Soriano talks about his pharmacy role in medication management and medication safety to deliver the best clinical care for residents.
In this segment, Julian talks about the traditional pharmacy model serving residential aged care and the limitations of the imprest process for dispensing medication. Soon into the project he saw the collaboration required with GPs and onsite nurses in dispensing medication for residents in end-of-life or palliative care. Julian sees the imprest process unable to support end-of-life residents, even being able to check the availability of medication.
But what most may not be aware of, is his rapid growth since starting the business in 2013 having just been in health care a few years earlier. Being part of a 2nd generation health care family, Shawn learnt from his father on site and at trade show visits overseas. Prior to HPA, he spent 2 years working in fit-outs of operating theatres, neo-natal and general population ICU, throughout being more fascinated with what he saw. -
Landmark research projects tackle critical issues in emergency healthcare
For two decades, the demand for emergency department services in Australia has outpaced population growth and wait times have increased. In 2022-2023 more than 8.8 million emergency department presentations occurred nationwide.
While demand is a contributing factor, EDs are currently being impacted by various factors across the entire health system.
The Emergency Medicine Foundation (EMF) is a non-profit organisation funding innovative Australian research that improves the way people are cared for in a medical emergency. The aim of the research is to deliver better and more effective health services to save lives and money.
-
Cardinal Health brings device reprocessing plant to Australia
Cardinal Health is global medical products manufacturer and leading provider of single-use device reprocessing services in the U.S. In Australia and New Zealand, as one of the largest suppliers of medical devices, announced on 23 May 2024 that it will be opening a single-use medical device reprocessing facility in Australia – its first reprocessing facility outside the United States.
On 18 March 2025 at the Health Innovation Living Lab at the John Hunter Hospital, a further announcement was made, on the chosen single-use medical device remanufacturing facility in Beresfield, Newcastle, set to commence operation late 2025, supported by the NSW Department of Primary Industries and Regional Development.